HOME
The Info List - The Aventis Prizes For Science Books


--- Advertisement ---



Sanofi
Sanofi
S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales.[3] The company was formed as Sanofi- Aventis
Aventis
in 2004 by the merger of Aventis
Aventis
and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi
Sanofi
in May 2011. The company is a component of the Euro
Euro
Stoxx 50 stock market index.[4] Sanofi
Sanofi
engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi
Sanofi
Pasteur).[5]

Contents

1 History

1.1 Sanofi-Synthélabo 1.2 Aventis

1.2.1 Sanofi- Aventis
Aventis
merger

1.3 Post-merger activities 1.4 Rename to Sanofi
Sanofi
and beyond 1.5 Company financials 1.6 Acquisition history

2 Products

2.1 Prescription medications

2.1.1 Autoimmune 2.1.2 Cardiovascular 2.1.3 Infectious disease 2.1.4 Metabolic 2.1.5 Neurology 2.1.6 Oncology 2.1.7 Pain 2.1.8 Diabetes 2.1.9 Over the counter

2.2 Pipeline 2.3 Management 2.4 Stockholders

3 Head office 4 Collaborative research 5 Sanofi
Sanofi
Pasteur

5.1 BCG supply shortage 2012-

6 Associations 7 Aventis
Aventis
Foundation 8 See also 9 Notes 10 References 11 External links

History[edit] Sanofi-Synthélabo[edit] Sanofi
Sanofi
was founded in 1973[6] as a subsidiary of Elf Aquitaine
Elf Aquitaine
(a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company. In 1993 Sanofi
Sanofi
made a move into the Eastern Europe market by acquiring a controlling interest in Chinoin, a Hungarian drug company that had about US$104 million in sales in 1992.[7][8] In that same year, Sanofi's made its first significant venture into the U.S., and strengthened its presence in Eastern Europe, by first partnering with Sterling Winthrop and then acquiring the prescription pharmaceuticals business in 1994.[7][9] Sanofi
Sanofi
was incorporated under the laws of France
France
in 1994 as a société anonyme, a form of limited liability company.[10]:18 Synthélabo
Synthélabo
was founded in 1970 through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834) and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L’Oréal
L’Oréal
acquired the majority of its share capital.[10]:19 In 1991, Synthelabo acquired Laboratories Delalande[11] and Laboratoires Delagrange, and through this deal picked up the product metoclopramide.[12][13] Sanofi- Synthélabo
Synthélabo
was formed in 1999 when Sanofi
Sanofi
merged with Synthélabo; at the time of the merger Sanofi
Sanofi
was the second largest pharmaceutical group in France
France
in terms of sales and Synthélabo
Synthélabo
was the third largest. The merged company was based in Paris, France.[10]:18–19[14] The merged companies focused on pharmaceuticals, divesting several businesses soon after the merger, including beauty, diagnostics, animal health and nutrition, custom chemicals, and two medical equipment businesses.[10]:19 Aventis[edit]

Aventis
Aventis
was formed in 1999 when French company Rhône-Poulenc
Rhône-Poulenc
S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG
Hoechst AG
with Cassella, Roussel Uclaf
Roussel Uclaf
and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.[15]:13[16]:9–11[17]:40–41 At the time of the merger, Rhône-Poulenc's business included the pharmaceutical businesses Rorer, Centeon (blood products), and Pasteur Merieux (vaccines), the plant and animal health businesses Rhône-Poulenc
Rhône-Poulenc
Agro, Rhône-Poulenc
Rhône-Poulenc
Animal Nutrition, and Merial, and a 67 percent share in Rhodia, a speciality chemicals company.[16]:10 Hoechst had seven primary businesses: Hoechst Marion Roussel (pharmaceuticals), AgrEvo
AgrEvo
(a joint venture with Schering in crop protection agents and pest control products), HR Vet (veterinary products), Dade Behring (diagnostics), Centeon, Celanese
Celanese
(chemicals), and Messer (chemicals).[16]:9 Merieux has been in the business of selling blood products, and In the 1980s during the AIDS epidemic, Merieux and other companies were involved in scandals related to HIV-contaminated haemophilia blood products that were sold to developing nations.[18] In mid 2000 Aventis
Aventis
and Millennium Pharmaceuticals, a US biotechnology company formed to discover new drugs based on the then-new science of genomics, announced that Aventis
Aventis
would make a $250M investment in Millennium and would pay $200M to Millennium in research fees over five years, one of the largest such deals between a big pharmaceutical company and a biotech company at the time.[19] In late 2000, in the midst of the recall of Starlink, its genetically modified maize product, Aventis
Aventis
announced that it had determined to sell off Aventis
Aventis
Cropscience, the seed and pesticide business unit it had created from the agriculture businesses of its predecessors.[20] In October 2001, Bayer
Bayer
and Aventis
Aventis
announced that Bayer
Bayer
would acquire the unit for about $6.6 billion, with the unit becoming Bayer CropScience and making Bayer
Bayer
the world's second-largest agrochemical company behind Syngenta.[21] In 2003 Aventis
Aventis
entered into a collaboration with Regeneron, a New York biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, in the field of cancer, which was then in Phase I clinical trials. Aventis
Aventis
invested $45 million in Regeneron
Regeneron
and made an upfront payment of $80 million in cash.[22] Regeneron
Regeneron
partnered the drug with Bayer
Bayer
Healthcare in the field of proliferative eye diseases, and under the name Eylea it was approved by the FDA in 2011;[23] after several setbacks in clinical trials,[24] Regeneron
Regeneron
and Sanofi
Sanofi
got the drug approved in metastatic colorectal cancer in combination with other agents, under the brand name ZALTRAP in 2012.[25] Sanofi- Aventis
Aventis
merger[edit] Sanofi- Aventis
Aventis
was formed in 2004 when Sanofi- Synthélabo
Synthélabo
acquired Aventis. In early 2004, Sanofi- Synthélabo
Synthélabo
made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis
Aventis
rejected the bid because it felt that the bid offered inferior value based on the company's share value, and the board of Aventis
Aventis
went so far as to enact poison pill provisions and to invite Novartis
Novartis
to enter merger negotiations.[26] The three-month takeover battle concluded when Sanofi- Synthélabo
Synthélabo
launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. The French government played a strong role, desiring what it called a "local solution", by putting heavy pressure on Sanofi- Synthélabo
Synthélabo
to raise its bid for Aventis
Aventis
and for Aventis
Aventis
to accept the offer[27] and by rejecting Aventis' poison pill proposal.[28] One of the largest risks in the deal for both sides, was the fate of the patents protecting Clopidogrel
Clopidogrel
(Plavix) which was one of the top-selling drugs in the world at the time and the major source of Sanofi's revenue.[29] Post-merger activities[edit] In 2006, Iraqis infected with HIV sued Sanofi
Sanofi
and Baxter due to HIV-contaminated haemophilia blood products sold by Merieux in the 1980s.[30] In 2006 the US patents on clopidogrel (Plavix) were challenged when a Canadian generics company, Apotex, filed an Abbreviated New Drug Application
Abbreviated New Drug Application
under the Hatch-Waxman Act, received FDA approval, and started marketing a generic clopidogrel. While Sanofi- Aventis
Aventis
and its partner on the drug, Bristol Myers Squibb (BMS), were able to get an injunction to stop Apotex from selling the drug,[31] the case became complicated when settlement negotiations fell apart twice - the second time due to an oral agreement made by BMS CEO Peter Dolan that BMS failed to disclose to the Federal Trade Commission during the review of the settlement agreement to ensure that it did not violate antitrust law. When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan being fired by BMS.[32] Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/ Sanofi
Sanofi
in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent,[33] which it paid in full by February 2012.[34] Apotex also sued BMS and Sanofi
Sanofi
for $3.4 billion for allegedly breaching the settlement agreement, and Apotex lost a jury trial in March 2013.[35] In 2007 Sanofi- Aventis
Aventis
expanded on Aventis' prior relationship with Regeneron; in the new deal Sanofi- Aventis
Aventis
agreed to pay Regeneron
Regeneron
$100 million each year for five years, under which Regeneron
Regeneron
would use its monoclonal antibody discovery platform to create new biopharmaceuticals, which Sanofi- Aventis
Aventis
gained the exclusive right to co-develop.[36] In 2009 the companies expanded the deal to $160 million per year and extended it through 2017.[36][37] As of 2009 the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the interleukin-6 receptor as a treatment for rheumatoid arthritis, another targeted nerve growth factor for the treatment of pain, and another targeted delta-like ligand 4 as a treatment of cancer.[37] Between 2008, when Chris Viebacher was hired as CEO, and 2010, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms especially in emerging markets, in the face of looming patent cliffs and the growth of the consumer healthcare segment.[38][39][40] In September, for about Zentiva was acquired for €1.8 billion, expanding the groups eastern European markets presence [41] In 2009, Medley Farma, the third largest pharmaceutical company in Brazil and a leading generics company in that country was acquired for about $635 million[42] Sanofi
Sanofi
outbid Teva Pharmaceuticals.[43] The deal was approved by Brazil's antitrust authorities in May 2010.[42] Later in the same year Indian vaccine manufacturer Shantha Biotechnics was acquired for $784 million[44] In October Sanofi- Aventis
Aventis
announced that it would lay off about 1,700 US employees (about 25% of its US workforce) due to restructuring triggered by growing generic competition and other factors, and that the company would focus its US operations on diabetes, atrial fibrillation and oncology.[45] In 2010 U.S. consumer healthcare company Chattem, Inc. was acquired for around $1.9 billion.[40] In the same year, Nepentes Pharma was acquired for $130 million and BMP Sunstone Corporation for $520.6 million.[46] Rename to Sanofi
Sanofi
and beyond[edit] The company dropped the - Aventis
Aventis
suffix of its name on 6 May 2011 after receiving approval at its annual general meeting. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.[47] In 2011, for around $20.1 billion, Genzyme
Genzyme
Corporation, a biotechnology company headquartered in Cambridge, Massachusetts and specialized in the treatment of orphan diseases, renal diseases, endocrinology, oncology and biosurgery.[48] In January 2012, Sanofi
Sanofi
co-invested in the $125 million Series A financing of Warp Drive Bio. Sanofi
Sanofi
sought support for its internal cancer research program and also took on an obligation to acquire Warp Drive if certain milestones were met.[49] In January 2014, Genzyme
Genzyme
and Alnylam Pharmaceuticals, a US biotechnology company developing RNAi
RNAi
therapeutics, announced that Genyzme would invest $700 million in Alnylam. Under the deal, Genzyme obtained further rights to patisiran, an RNAi
RNAi
treatment for transthyretin-mediated amyloidosis - a condition that can result in familial amyloidotic polyneuropathy and familial amyloidotic cardiomyopathy,[50] and obtained rights to other compounds in Alnylam's pipeline.[51] In March 2014 Sanofi
Sanofi
joined the bidding for Merck & Co.’s over-the-counter health-products unit, the maker of Coppertone sunblock and Claritin allergy medicine; bids were expected to range between $10 billion and $12 billion.[52] In October 2014, Sanofi's directors fired US-resident chief executive Chris Viehbacher, blaming his alleged lack of communication with the board and poor execution of his strategy.[53] Board chairperson Serge Weinberg took over as interim CEO until 2 April 2015 when Bayer Healthcare board chairperson Olivier Brandicourt
Olivier Brandicourt
(appointed by Sanofi on 19 February 2015[54]) took over. Before Brandicourt even started his new job, French government ministers Stéphane Le Foll
Stéphane Le Foll
and Ségolène Royal
Ségolène Royal
attacked the $4.5 million golden handshake he was getting from Sanofi
Sanofi
- and his pay of about $4.7 million a year.[55] Further, in 2014, the business took a 66% stake in Globalpharma, Dubai-based generics manufacturer.[56] In July 2015, Genzyme
Genzyme
announced it would acquire the rare cancer drug Caprelsa (vandetanib) from AstraZeneca
AstraZeneca
for up to $300 million.[57] In the same month In July 2015, the company announced a new global collaboration with Regeneron
Regeneron
to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[58] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.[59] In June 2016, the company announced it had struck an asset-swap deal with Boehringer Ingelheim, Sanofi
Sanofi
would sell its Merial
Merial
animal health division (valuing it at €11.4 billion), whilst acquiring Boehringers consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash. The deal means Sanofi
Sanofi
is now one of the global consumer healthcare leaders by market share.[60] In July 2017, the company announced its intention to acquire Protein Sciences, a privately held, Connecticut-based vaccines biotechnology company, for $650 million and with up to $100 million in milestone achievements.[61] In January 2018, Sanofi
Sanofi
announced that it would acquire Bioverativ for $11.6 billion[62] and days later announced it would acquire Ablynx for €3.9 billion ($4.8 billion).[63] Company financials[edit]

Historical financial data (in billions of euro)[64][65][66][1]

Year 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Revenue 6.069 7.448 8.048 14.87 27.31 28.37 28.05 27.57 29.31 30.38 33.39 34.95 30.97 31.69 34.54 33,82

Net Income 1.098 1.640 1.865 -3.665 2.202 4.006 5.263 3.851 5.265 5.467 5.646 4.888 3.716 4.390 4.287 4.800

Assets 18.23 17.36 17.42 82.85 86.24 77.76 71.91 71.99 80.25 85.26 100.7 100.4 96.06 97.39 102.3 104.7

Equity 12.75 12.60 12.74 41.63 46.40 45.60 44.54 44.87 48.32 53.10 56.19 57.35 56.9 56.12 58.05 57.72

Note. In 2001—2004 — Sanofi-Synthélabo, in 2004—2011 — Sanofi-Aventis. Acquisition history[edit] The following is an illustration of the company's major mergers, acquisitions and historical predecessors:

Sanofi

Sanofi–Aventis

Aventis (Merged 2004)

Rhône-Poulenc (Merged 1999)

Rorer

Centeon

Pasteur Merieux

Rhône-Poulenc
Rhône-Poulenc
Agro

Rhône-Poulenc
Rhône-Poulenc
Animal Nutrition

Merial

Rhodia

Hoechst Marion Roussel

Hoechst Marion Roussel

AgrEvo

HR Vet

Dade Behring

Centeon

Celanese

Messer

Aventis
Aventis
Cropscience (Spun off 2000)

Sanofi-Synthélabo (Merged 1999)

Sanofi

Sanofi (Founded 1973 as subsidiary of Elf Aquitaine)

Midy (Founded 1717)

Sterling Winthrop (Acq 1994)

Synthélabo

Laboratoires Dausse (Founded 1834, merged 1970)

Robert & Carrière (Founded 1899, merged 1970)

Zentiva (Acq 2008)

Sicomed SA Bucharest (Acq 2005)

Leciva Slovakofarma (Acq 2003)

Medley Farma (Acq 2009)

Shantha Biotechnics (Acq 2009)

Chattem (Acq 2010)

Nepentes Pharma (Acq 2010)

BMP Sunstone Corporation (Acq 2010)

Genzyme Corporation (Acq 2011)

Whatman Biochemicals Ltd (Acq 1981)

 

Koch-Light Laboratories (Acq 1982)

 

Integrated Genetics (Acq 1989, IPO 1991)

 

Genecore International (Diagnostic enzyme div, Acq 1991)

 

Medix Biotech, Inc. (Acq 1992)

 

Enzymatix Ltd (Acq 1992)

 

Vivigen (Acq 1992)

 

Virotech (Acq 1993)

 

Omni Res srl (Acq 1993)

 

Sygena Ltd (Acq 1994)

 

BioSurface Technology Inc. (Acq 1994)

 

TSI Inc. (Acq 1994)

 

PharmaGenics, Inc. (Acq 1997)

 

Biomatrix (Acq 2000)

 

SangStat Medical Corp. (Acq 2003)

 

Ilex Oncology
Oncology
Inc. (Acq 2004)

 

Bone Care International Inc. (Acq 2005)

 

AnorMED Inc. (Acq 2006)

 

Bioenvision (Acq 2007)

Merial ( Asset
Asset
swap with Boehringer Ingelheim
Boehringer Ingelheim
for their Consumer Healthcare div, 2016)

Boehringer Ingelheim (Consumer Healthcare div, 2016)

Protein Sciences (Acq 2017)

Bioverativ (Acq 2018)

True North Therapeutics (Acq 2017)

Ablynx (Acq 2018)

Products[edit] Prescription medications[edit] Autoimmune[edit]

Epinephrine autoinjector
Epinephrine autoinjector
(Auvi-Q in the US and Allerject in Canada), licensed from Intelliject[67] and approved by the FDA in 2012 for emergency treatment of life-threatening allergic reactions.[68] Teriflunomide
Teriflunomide
(Aubagio), small molecule for multiple sclerosis. Approved by the FDA in September 2012.[69]

Product Recall and Effects: The Epinephrine auto-injection devices made by Sanofi
Sanofi
SA currently on the market in the U.S. and Canada were voluntarily recalled on October 28, 2015.[70][71] The reason stated by Sanofi
Sanofi
was that the products have been found to potentially have inaccurate dosage delivery, which may include failure to deliver drug.[72][73] Sanofi
Sanofi
US also added the following warning: If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life‑threatening condition.[72] In its news Release on October 28, 2015, Sanofi
Sanofi
Canada stated that it was "actively working with suppliers of alternative epinephrine auto-injectors to have a full stock available in Canada as soon as possible. Canadian customers were asked to immediately return the Allerject product to their local pharmacy to obtain an alternate epinephrine auto-injector."[74] The U.S. Food and Drug Administration
Food and Drug Administration
also filed a news release[73] confirming that the recall involves all Auvi-Q currently on the market in the U.S. The FDA release went on to provide information for consumers re: exchanging the device for another brand of product, also provided on the Auivi-Q web site. Sanofi
Sanofi
US will provide reimbursement for out of pocket costs incurred for the purchase of new, alternate epinephrine auto-injectors with proof of purchase. The alternate products expected to most commonly replace the recalled Sanofi
Sanofi
devices are the EpiPens made by Mylan
Mylan
in the US and by Pfizer—under license from Mylan—in Canada.[75] Mylan
Mylan
already had an 85% market share of the auto-injectors in the US[76] in the first half of 2015. Maylan is expected to benefit from the recall by its competitor Sanofi, according to a report published in the Fierce Pharma newsletter of November 2, 2015: ".... it is very hard to see Auvi-Q returning to the market, as it will need to be redesigned and face uphill battle to recapture patient trust after the recall," Bernstein analyst Ronny Gal wrote in a note to clients on Monday.[77] Gal also believes that the company will eventually have 95% of the Epinephrine auto-injector market, according to another Fierce Pharma report on November 3, 2015.[78] Cardiovascular[edit]

Clopidogrel
Clopidogrel
(Plavix, Iscover) for atherothrombosis Enoxaparin
Enoxaparin
(Lovenox, Clexane) for thrombosis (its biggest seller in 2008)[79] Mipomersen
Mipomersen
(Kynamro), an antisense drug invented by Isis Pharmaceuticals and acquired by Genzyme
Genzyme
in 2008 (pre-Sanofi)[80] and approved by the FDA in 2013 for the orphan disease homozygous familial hypercholesterolemia.[81] Irbesartan
Irbesartan
(Aprovel, Avapro, Karvea) and Ramipril
Ramipril
(Delix, Triatec, Tritace) for hypertension Alirocumab (Praluent) for heterozygous familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease dupilumab (Dupixent) for heart disease

Infectious disease[edit]

Antibiotics:

Cefotaxime
Cefotaxime
(Claforan) Rifapentine
Rifapentine
(Priftin) Levofloxacin
Levofloxacin
(Tavanic) Amoxicillin/clavulanic acid
Amoxicillin/clavulanic acid
(Amoklavin)

Vaccines:

Bacterial diseases:

Cholera Diphtheria Haemophilus influenzae type b Meningococcal infections (Menactra) Pertussis Pneumococcal infections Tetanus Tuberculosis Typhoid Fever

Viral diseases:

Hepatitis A Hepatitis B Influenza Japanese Encephalitis
Japanese Encephalitis
(Ixiaro) Measles Mumps Poliomyelitis Rabies Rubella Varicella Yellow Fever Smallpox
Smallpox
- eradicated in 1980 (vaccine produced as a measure in response to the threat of bioterrorism)

Metabolic[edit]

Glimepiride
Glimepiride
(Amaryl) for type 2 diabetes mellitus Human Insulin
Insulin
(Insuman) for type 1 and type 2 diabetes mellitus Insulin
Insulin
glulisine (Apidra) and Insulin
Insulin
glargine (Lantus) for diabetes Risedronic acid
Risedronic acid
(Actonel) for osteoporosis and Paget’s disease Sevelamer
Sevelamer
hydrochloride (Renagel and Renvela) for end stage renal disease carmustine implants (Gliadel) for cancer

Neurology[edit]

Sodium hyaluronate
Sodium hyaluronate
(Hyalgan) for Blood Tests Valproic acid
Valproic acid
(Depakine) and Valproate semisodium
Valproate semisodium
(Depakote) for epilepsy Zolpidem
Zolpidem
(Ambien, Ambien CR, Myslee, Stilnoct, Stilnox, Zolfresh, Zolt) for insomnia

Oncology[edit]

Alfuzosin
Alfuzosin
(Xatral/Uroxatral) for benign prostatic hyperplasia Cabazitaxel
Cabazitaxel
(Jevtana) for prostate cancer Plerixafor
Plerixafor
(Mozobil) macrocycle approved by the FDA for peripheral blood stem cell mobilizer for non-Hodgkins lymphoma and multiple myeloma in December 2008.[82] Aflibercept
Aflibercept
(ZALTRAP) recombinant fusion protein, approved in metastatic colorectal cancer in combination with other agents in 2012.[25] Clomifene
Clomifene
(Clomid) for Female infertility Docetaxel
Docetaxel
(Taxotere) for breast, lung and prostate cancer Oxaliplatin
Oxaliplatin
(Eloxatin) for colorectal cancer Sarilumab
Sarilumab
(Kevzara) for Blood Tests, lung and prostate cancer vandetanib (Caprelsa) for breast, colorectal cancer and Female infertility

Pain[edit]

Codeine
Codeine
(Solpadol) for Chronic pain Ketoprofen
Ketoprofen
(Bi-profined) for pain

Diabetes[edit]

Toujeo
Toujeo
(insulin glargine) for type 1 and type 2 diabetes mellitus Lantus
Lantus
(insulin glargine) for type 1 and type 2 diabetes mellitus

Over the counter[edit]

Fexofenadine
Fexofenadine
(Allegra, Telfast) and Triamcinolone
Triamcinolone
(Nasacort) for allergic rhinitis Paracetamol
Paracetamol
(Novaldol) Calcium carbonate (Maalox, an antacid)

The company also produces a broad range of over-the-counter products, among them Allegra, IcyHot
IcyHot
for muscle pain, Gold Bond
Gold Bond
for skin irritation, and Selsun Blue dandruff shampoo (these brands were acquired in 2010 when Sanofi- Aventis
Aventis
purchased Chattem). Pipeline[edit] As of the summer of 2013, Sanofi
Sanofi
was in a race with Amgen
Amgen
and Pfizer to win approval for a drug that inhibits PCSK9, a protein that slows the clearance of low-density lipoprotein (LDL) cholesterol - the form of cholesterol that leads to heart attacks.[83] Sanofi's drug was discovered by Regeneron
Regeneron
and is called alirocumab.[84] An FDA warning in March 2014 about possible cognitive adverse effects of PCSK9 inhibition threw the competition into disarray, as the FDA asked companies to include neurocognitive testing into their Phase III clinical trials.[85] In fall 2013 Sanofi
Sanofi
announced that another candidate from its collaboration with Regeneron, the monoclonal antibody against the interleukin 6 receptor, sarilumab, had better efficacy than placebo in its first Phase III trial for rheumatoid arthritis.[86] Management[edit]

Olivier Brandicourt, Chairman, Chief executive officer[87] Jean-François Dehecq was the General Manager of Sanofi
Sanofi
from its creation in 1973 until 2007.

Stockholders[edit] As of 31 December 2013:[88]:185

Breakdown of share ownership: 8.93% by L'Oréal, 0.27% treasury shares and 1.31% employees. The remaining 89.49% were publicly traded.[A]

Head office[edit]

Head office 54 rue de la Boétie, Paris 8th around.

Former head office 174 avenue de France, Paris 13th around.

In January 2012, Sanofi
Sanofi
moved its head office location to 54, Rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent. Sanofi's previous head office was located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominant style of the area surrounding the François Mitterrand Library. After Sanofi
Sanofi
and Aventis
Aventis
merged, the employees at the former Aventis
Aventis
head office in Schiltigheim, Alsace
Alsace
moved to Paris.[90] In June 2015, the headquarters were moved to Gentilly, just south of Paris.

Collaborative research[edit] In addition to internal research and development activities Sanofi
Sanofi
is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox project[91][92] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative
Innovative Medicines Initiative
of EFPIA and the European Commission.[93] In June 2010, Sanofi
Sanofi
and the Charite University of Berlin
Berlin
signed a cooperation agreement for the research and development of medicines and therapies.[94] On 25 October 2012, Sanofi
Sanofi
said its earnings for the third quarter slumped as generic competitors ate into profits of its Eloxatin
Eloxatin
cancer treatment.[95] Sanofi
Sanofi
Pasteur[edit] Main article: Sanofi
Sanofi
Pasteur In 2005 Sanofi
Sanofi
Pasteur, vaccines division of Sanofi
Sanofi
Group, was awarded a $97 Million HHS contract in 2005.[96] BCG supply shortage 2012-[edit] In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold.[97] The facility, located in Toronto, Ontario, Canada, produced BCG vaccine
BCG vaccine
products, made with the Glaxo 1077 strain,[98] such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits.[97] The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines.[99] The Toronto Sanofi plant[100] On October 29, 2014 Health Canada
Health Canada
gave the permission for Sanofi
Sanofi
to resume production of BCG.[101] Associations[edit] Sanofi
Sanofi
is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA),[102] Biotechnology Industry Organization (BIO),[103] and Pharmaceutical Research and Manufacturers of America (PhRMA).[104] Sanofi's vaccine subsidiary, Sanofi
Sanofi
Pasteur, is a member of EuropaBio.[105] Aventis
Aventis
Foundation[edit] The Aventis
Aventis
Foundation,[106] a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.[citation needed] See also[edit]

Aventis
Aventis
Pharma Sanofi
Sanofi
Biogenius Canada

Paris portal Companies portal

Notes[edit]

^ Total reduced its stake to less than 5% in 2011.[89]

References[edit]

^ a b c d e f "Annual Report 2016". Sanofi
Sanofi
S.A. 2017-02-08. Retrieved 2017-02-25.  ^ " Sanofi
Sanofi
2016 Factsheet" (PDF). Sanofi
Sanofi
S.A. Retrieved 25 February 2017.  ^ Eric Palmer and Carly Helfand for FiercePharma. 4 March 2014 The top 10 pharma companies by 2013 revenue ^ "Börse Frankfurt (Frankfurt Stock Exchange): Stock market quotes, charts and news". www.boerse-frankfurt.de. Retrieved 23 May 2017.  ^ "Sanofi- Aventis
Aventis
to sign deal to build flu vaccine plant in China - source". AFX News. Forbes. 23 November 2007. Retrieved 2009-04-19.  ^ "Le fondateur de Sanofi
Sanofi
est mort". lexpress.fr. Retrieved 4 June 2015.  ^ a b Staff, The Pharma Letter. Sept 20, 1993 Sanofi
Sanofi
Extends Holding in Chinoin ^ Chinoin listing in at securities.com Page accessed Feb 5, 2016 ^ Collins, Joseph C.; Gwilt, John R. (2000). "The Life Cycle of Sterling Drug, Inc" (PDF). Bull. Hist. Chem. 25 (1): 22–27.  ^ a b c d Sanofi- Synthélabo
Synthélabo
Form 20F for the Fiscal Year ended 31 December 2002 ^ Denis Cosnard for Les Echos. December 11, 1991. Synthélabo
Synthélabo
s'offre Delalande ^ Denis Conard for Les Echos. Oct 17, 1991 Synthélabo
Synthélabo
rachète les laboratoires Delagrange ^ Bibliothèque nationale de France
France
Laboratoires Delagrange Page accessed Aug 24, 2016 ^ Tom Meek for PMLiVE May 24, 2013 A look back at Sanofi's merger with Synthélabo ^ Aventis
Aventis
Form 20-F for the fiscal year ended 31 December 2002 ^ a b c Arturo Bris and Christos Cabolis, Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis, Chapter 4 in Corporate Governance and Regulatory Impact on Mergers and Acquisitions: Research and Analysis on Activity Worldwide Since 1990. Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 26 July 2007 ^ Lawton Robert Burns The Business of Healthcare Innovation Cambridge University Press, 26 July 2012 ^ Meier, Barry (1996-06-11). "Blood, Money and AIDS: Haemophiliacs Are Split; Liability Cases Bogged Down in Disputes". The New York Times.  ^ Andrew Pollack for the New York Times. 24 June 2000 Aventis
Aventis
Unit Sets Big Investment in Biotechnology Start-Up ^ New York Times, 16 November 2000 Aventis
Aventis
to Sell Agriculture Unit ^ CNN Money. 2 October 2001 Bayer
Bayer
buys CropScience ^ Candace Hoffmann for First Word Pharma. 8 September 2003 Aventis inks deal with Regeneron
Regeneron
for collaboration on cancer therapy ^ Gever, John (19 November 2011). "FDA Approves Eylea for Macular Degeneration". MedpageToday.com. Retrieved 2013-10-16.  ^ Ciombor KK et al. Aflibercept
Aflibercept
Clin Cancer
Cancer
Res. 15 Apr 2013; 19(8): 1920–1925. PMID 23444216 ^ a b "Ziv-Aflibercept". FDA Drug Approvals Database. Food and Drug Administration. 3 August 2012. Retrieved 2013-10-16.  ^ Heather Timmons for the New York Times. 3 April 2004 Aventis
Aventis
Invites Novartis
Novartis
To Counter Sanofi's Bid ^ Heather Timmons for the New York Times. 27 April 2004 France
France
Helped Broker the Aventis- Sanofi
Sanofi
Deal ^ New York Times 24 April 2004 Aventis
Aventis
Plan Is Rejected ^ Kimberly S Cleaves and Ann M Thayer Warning, merge with care: Sanofi- Aventis
Aventis
Modern Drug Discovery, August 2004:21-26 ^ Paul von Zielbauer for the New York Times. 4 September 2006 Iraqis Infected by H.I.V.-Tainted Blood Try New Tool: A Lawsuit ^ BMS Press Release. 8 December 2006 Preliminary Injunction Against Apotex Upheld on Appeal ^ Aaron Smith for CNNMoney.com 26 October 2006 Bristol CEO Dolan gets fired: Company says it heeded request of a federal monitor ^ Donald Zuhn for Patent Docs. 9 November 2011 Sanofi- Aventis
Aventis
v. Apotex Inc. (Fed. Cir. 2011) ^ Linda a. Johnson for Associated Press 8 February 2012 Apotex pays Bristol, Sanofi
Sanofi
damages over Plavix
Plavix
Archived 5 March 2016 at the Wayback Machine. ^ Carolina Bolado for Law360 14 March 2013. Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix
Plavix
Deal ^ a b Ron Winslow for the Wall Street Journal. 10 Nov. 2009 Sanofi Expands Regeneron
Regeneron
Deal ^ a b Genetic Engineering and Biotechnology News. 11 Nov 2009 Sanofi- Aventis
Aventis
Commits Over $2.8B to Regeneron
Regeneron
in mAb Discovery Alliance ^ FierceBiotech. Sanofi-Aventis: A timeline of biopharma deals ^ Andy Tisman for IMS Health 2010 The Rising Tide of OTC in Europe ^ a b Reuters, 21 December 2009 Drug Maker Sanofi- Aventis
Aventis
Buys Chattem for $1.9 Billion ^ New York Times. 22 September 2008 Sanofi- Aventis
Aventis
to buy Czech generic drug maker ^ a b Leigh Kamping-Carder for Law360. 20 May 2010 Brazil Clears Sanofi's $635M Medley Pharma Buy ^ Gareth Macdonald for PharmaTechnologist, 15 April 2009 Sanofi
Sanofi
beats Teva in Medley melee ^ " Sanofi
Sanofi
snaps up India's Shantha for $784M". FierceBiotech.  ^ Thomas Gryta and Mimosa Specer for the Wall Street Journal. Updated 9 Oct. 2010 Sanofi
Sanofi
Cuts Jobs, Counters Genzyme ^ Phil Serafino for Bloomberg News. 28 October 2010 Sanofi- Aventis
Aventis
to Buy BMP Sunstone to Expand in China ^ Mennella, Noelle (6 May 2011). " Sanofi
Sanofi
changes name, pace of acquisitions to slow". Reuters. Retrieved 7 May 2011.  ^ Chris V. Nicholson for the New York Times' Dealbook. 16 February 2011 Sanofi
Sanofi
Agrees to Buy Genzyme
Genzyme
for $20.1 Billion ^ Arlene Weintraub for Xconomy. 10 January 2012 Warp Drive Bio Launches With $125M from Third Rock, Greylock, Sanofi ^ Alnylam, TTR Amyloidosis
Amyloidosis
(FAP) ^ Chad Bray for the New York Times' Dealbook. 13 January 2014 Sanofi Unit to Buy $700 Million Stake in Rare Disease Company ^ Bloomberg News [1] 24 March 2014 ^ French drugmaker Sanofi
Sanofi
sacks CEO, shares drop, Natalie Huet and Noëlle Mennella, Reuters
Reuters
news agency, New York 29 October 2014.Retrieved: 6 July 2015. ^ Sanofi : Sanofi
Sanofi
Appoints Olivier Brandicourt
Olivier Brandicourt
as Chief Executive Officer, Sanofi
Sanofi
corporate website, 19 February 2015.Retrieved: 6 July 2015. ^ French Government Slams Sanofi
Sanofi
Over Brandicourt Pay Package, The Wall Street Journal, 24 February 2015].Retrieved: 6 July 2015. ^ Eric Palmer (2014-06-26). " Sanofi
Sanofi
buys Dubai's Globalpharma to produce generics in the Middle East". Questex LLC. Retrieved 2017-02-24.  ^ " Genzyme
Genzyme
to Buy Caprelsa from AstraZeneca
AstraZeneca
for Up to $300M - GEN News Highlights - GEN".  ^ "Regeneron, Sanofi
Sanofi
Launch $2B+ Immuno- Oncology
Oncology
Collaboration - GEN News Highlights - GEN".  ^ "UPDATED: Struggling Sanofi
Sanofi
paying $1.8B to partner with Regeneron on immuno-oncology - FierceBiotech".  ^ "Aiming for top dog status, Sanofi
Sanofi
and Boehringer swap animal and consumer health units - FiercePharma".  ^ http://mediaroom.sanofi.com/sanofi-to-acquire-protein-sciences/ ^ https://www.reuters.com/article/us-biotech-m-a/biotech-ma-takes-off-as-sanofi-and-celgene-spend-20-billion-idUSKBN1FB20V ^ https://uk.reuters.com/article/uk-ablynx-m-a-sanofi/sanofi-beats-novo-to-buy-ablynx-for-3-9-billion-euros-in-biotech-ma-boom-idUKKBN1FI0PJ ^ "Annual Report 2005 on SEC Filing Form 20-F". Sanofi. 2006-03-31. Retrieved 2017-02-22.  ^ "Annual Report 2010 on SEC Filing Form 20-F". Sanofi. 2011-03-01. Retrieved 2017-02-22.  ^ "Annual Report 2015 on SEC Filing Form 20-F". Sanofi. 2016-03-04. Retrieved 2017-02-22.  ^ http://www.kaleopharma.com/intelliject-inc-receives-fda-approval-for-auvi-qtm-epinephrine-injection-usp/ ^ Katie Thomas for the New York Times. 1 February 2013 Brothers Develop New Device to Halt Allergy Attacks ^ "FDA approves new multiple sclerosis treatment Aubagio" (Press release). US FDA. Retrieved 2012-09-14.  ^ "All Allerject epinephrine auto-injectors recalled".  ^ http://www.allerject.ca/Common/docs/en/Sanofi-Canada-Issues-Voluntary-Recall-of-Allerject.pdf ^ a b "Auvi-Q® (epinephrine injection, USP)".  ^ a b Commissioner, Office of Regulatory Affairs, Office of the. "Recalls, Market Withdrawals, & Safety Alerts - UPDATED: Sanofi
Sanofi
US Issues Voluntary Nationwide Recall of All Auvi-Q® Due to Potential Inaccurate Dosage Delivery". www.fda.gov. Retrieved 23 May 2017.  ^ " Sanofi
Sanofi
Canada Issues Voluntary Nationwide Recall of Allerject® Due to Potential Inaccurate Dosage".  ^ "Welcome to EpiPen® 101".  ^ Reprints, Cynthia Koons CynthiaLKoons Robert Langreth RobertLangreth. "How Marketing Turned the EpiPen Into a Billion-Dollar Business".  ^ "Sanofi's Auvi-Q recall puts Mylan's rival EpiPen in full control of blockbuster market - FiercePharma".  ^ "It's open season for Mylan's EpiPen as Sanofi, Teva stumble - FiercePharma".  ^ "Annual Review 2008" (PDF). Sanofi-Aventis. Retrieved 2009-04-19.  ^ Lisa M. Jarvis for Chemical and Engineering News. 14 January 2008 Isis, Genzyme
Genzyme
In Heart Drug Deal ^ Andrew Pollack for the New York Times. 29 January 2013 F.D.A. Approves Genetic Drug to Treat Rare Disease ^ "Mozobil approved for non-Hodgkin's lymphoma and multiple myeloma" (Press release). Monthly Prescribing Reference. 18 December 2008. Retrieved 3 January 2009.  ^ Gina Kolata for the New York Times. 9 July 2013 Rare Mutation Ignites Race for Cholesterol Drug ^ Alirocumab on Regeneron's website Archived 16 April 2012 at the Wayback Machine. ^ John Carroll for FierceBiotech 7 March 2014 UPDATED: Regeneron, Sanofi
Sanofi
and Amgen
Amgen
shares suffer on FDA's frets about PCSK9 class ^ John Carroll for FierceBiotech 22 November 2013 Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug ^ Noemie Bisserbe for the Wall Street Journal. 20 Feb. 2015 Sanofi Names Olivier Brandicourt
Olivier Brandicourt
CEO ^ "Annual Report 2013" (PDF). Sanofi-Aventis. Retrieved 13 April 2014.  ^ MarketWatch 29 April 2011 Total CFO says firm cut Sanofi
Sanofi
stake to under 5% ^ "Sanofi-Aventis : regroupement à Paris." Le Journal du Net. Retrieved on 28 September 2010. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.  ^ "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 2008-08-25.  ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 2009-10-15. Retrieved 2008-08-25.  ^ Sanofi-aventis, Charite University Sign Cooperation Agreement News article from InfoGrok. ^ " Sanofi
Sanofi
Earns Slump in Q3 as Competition Heats Up". The New York Times. 25 October 2012.  ^ " Sanofi
Sanofi
pasteur Awarded $97 Million HHS Contract to Accelerate Cell-Culture Pandemic Influenza
Influenza
Vaccine
Vaccine
Development". 4 January 2005. Retrieved 12 June 2013.  ^ a b "April 2012 Inspectional Observations (form 483)", U.S. Food and Drug Administration, Vaccines, Blood & Biologics, 12 April 2012, retrieved 29 January 2016  ^ Fine, P.E.M (2004). Issues relating to the use of BCG in immunization programmes: A discussion document, WHO/V&B/99.23 (PDF). Geneva: WHO. Archived from the original (PDF) on 21 October 2012.  ^ Palmer, Eric (10 September 2014), "Merck again shipping BCG cancer treatment but Sanofi
Sanofi
still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma  ^ Palmer, Eric (12 July 2012), "Merck again shipping BCG cancer treatment but Sanofi
Sanofi
still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma  ^ Palmer, Eric (31 March 2015), " Sanofi
Sanofi
Canada vax plant again producing ImmuCyst bladder cancer drug", FiercePharma, retrieved 29 January 2016  ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.  ^ BIO member list Accessed 19 April 2014 ^ PhRMA member list Accessed 19 April 2014 ^ EuropaBio
EuropaBio
member list Accessed 19 April 2014 ^ Home. Aventis
Aventis
Foundation (2013-11-27). Retrieved on 2013-12-23.

External links[edit]

Wikimedia Commons has media related to Sanofi.

Official website Aventis
Aventis
Foundation BIO IT world.com Sanofi
Sanofi
on Securities and Exchange Commission

v t e

Sanofi

Predecessors

Sanofi-Synthélabo Aventis Hoechst Rhône-Poulenc Cassella Roussel Uclaf Marion Merrell Dow

CEOs

Chris Viehbacher Olivier Brandicourt

Main products

Cardiovascular

Aprovel CoAprovel Tritace

Thrombosis

Plavix Clexane

Oncology

Taxotere Eloxatin

Diabetes

Amaryl Apidra Lantus

Central nervous system

Depakine Chrono

Internal medicine

Actonel Arava Avil Avipect Bi-Profenid Bronchicum Claforan Daonil Flagyl Hemoclar Lanzor Lasix Maalox Maalox Plus Proctosedyl Targocid Tavanic Telfast Trental

Chattem Inc.

Brands

Allegra Gold Bond ACT Mouthwash Balmex Diaper Rash Ointment Rolaids Cortizone-10 Flexall IcyHot Sun-In Ultra Swim Pamprin Premsyn Kaopectate Dexatrim Aspercreme Selsun Blue Nasacort Unisom Capzasin Benzodent Herpecin-L Garlique New Phase

v t e

Euro
Euro
Stoxx 50 companies of the Euro
Euro
Area

Last updated October 2015

Air Liquide Airbus Allianz Anheuser-Busch InBev ASML Holding Assicurazioni Generali AXA Banco Bilbao Vizcaya Argentaria Banco Santander BASF Bayer BMW BNP Paribas Carrefour Saint-Gobain Daimler AG Deutsche Bank Deutsche Post Deutsche Telekom Enel Engie
Engie
SA Eni E.ON Essilor
Essilor
International Fresenius SE Groupe Danone Iberdrola Inditex ING Group NV Intesa Sanpaolo L'Oréal LVMH
LVMH
Moët Hennessy Louis Vuitton Münchener Rückversicherungs-Gesellschaft Nokia Orange S.A. Philips Electronics SAFRAN Sanofi SAP SE Schneider Electric Siemens Société Générale
Société Générale
SA Telefónica Total S.A. Unibail-Rodamco UniCredit Unilever Vinci SA Vivendi Volkswagen Group

v t e

CAC 40
CAC 40
companies of France
France
(as of 4 October 2017)

Accor Air Liquide Airbus ArcelorMittal Atos AXA BNP Paribas Bouygues Capgemini Carrefour Crédit Agricole Danone Engie Essilor Kering L'Oréal LafargeHolcim Legrand LVMH Michelin Orange Pernod Ricard Peugeot Publicis Renault Safran Saint-Gobain Sanofi Schneider Electric Société Générale Sodexo Solvay STMicroelectronics TechnipFMC Total Unibail-Rodamco Valeo Veolia V

.